drugset / Trial / NCT00406003

Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects

NCT00406003

Phase 1 Completed 6 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The study was designed to describe the relationship between dose and pharmacokinetic parameters of paroxetine over the range of proposed dosage strengths of the paroxetine CR tablet (12.5 to 37.5 mg) as well as safety profile

Timeline

Start
2006-03-24
Primary completion
2006-04-26
Completion
2006-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 12.5 mg
Subject Paroxetine Small molecule 25 mg
Subject Paroxetine Small molecule 37.5 mg

Indications